Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-ketamine for myocardial protection in adult liver transplantation
ChiCTR2300075244Phase 4Not yet recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esketamine in hepatic disease (2 arms), sponsored by Tianjin First Central Hospital. Primary endpoints: cTn-I, CK-MB and 2 more. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
hepatic disease
Beyond the preview
Go deeper on ChiCTR2300075244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075244.